544 related articles for article (PubMed ID: 32546241)
61. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
[TBL] [Abstract][Full Text] [Related]
62. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
[TBL] [Abstract][Full Text] [Related]
63. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
64. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.
Molina ER; Chim LK; Salazar MC; Mehta SM; Menegaz BA; Lamhamedi-Cherradi SE; Satish T; Mohiuddin S; McCall D; Zaske AM; Cuglievan B; Lazar AJ; Scott DW; Grande-Allen JK; Ludwig JA; Mikos AG
Acta Biomater; 2019 Dec; 100():38-51. PubMed ID: 31542501
[TBL] [Abstract][Full Text] [Related]
65. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
66. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
67. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
68. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
69. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
70. The Crosstalk Between Hippo-YAP Pathway and Innate Immunity.
Wang S; Zhou L; Ling L; Meng X; Chu F; Zhang S; Zhou F
Front Immunol; 2020; 11():323. PubMed ID: 32174922
[TBL] [Abstract][Full Text] [Related]
71. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
72. TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer.
Han Y; Tang Z; Zhao Y; Li Q; Wang E
Mol Carcinog; 2018 Feb; 57(2):159-166. PubMed ID: 28926138
[TBL] [Abstract][Full Text] [Related]
73. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
74. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.
Matthews JM; Bhatt S; Patricelli MP; Nomanbhoy TK; Jiang X; Natkunam Y; Gentles AJ; Martinez E; Zhu D; Chapman JR; Cortizas E; Shyam R; Chinichian S; Advani R; Tan L; Zhang J; Choi HG; Tibshirani R; Buhrlage SJ; Gratzinger D; Verdun R; Gray NS; Lossos IS
Blood; 2016 Jul; 128(2):239-48. PubMed ID: 27151888
[TBL] [Abstract][Full Text] [Related]
75. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
76. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
77. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
78. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
Wang KJ; Wang C; Dai LH; Yang J; Huang H; Ma XJ; Zhou Z; Yang ZY; Xu WD; Hua MM; Lu X; Zeng SX; Wang HQ; Zhang ZS; Cheng YQ; Liu D; Tian QQ; Sun YH; Xu CL
Clin Cancer Res; 2019 Feb; 25(3):1070-1086. PubMed ID: 30397177
[TBL] [Abstract][Full Text] [Related]
79. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
[TBL] [Abstract][Full Text] [Related]
80. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
